FDA decision: Ivonescimab by Summit Therapeutics (in 2026)
$0.00
1
1
FDA decision: Ivonescimab by Summit Therapeutics (in 2026)
$0.00
1
1
AI Analysis
Trader mode: Actionable analysis for identifying opportunities and edge
About This Event
FDA decision on Ivonescimab in 2026 If the FDA's decision on Ivonescimab by Summit Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes. This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Ivonescimab (also called AK112 or SMT112) is a bispecific antibody — think of it as a single engineered drug molecule that carries two different "hooks" i
Current Market Outlook
Kalshi traders see the FDA approval of Ivonescimab by Summit Therapeutics in 2026 as a coin flip at 50%. That price tells you the market has no strong directional conviction. It is not saying approval is likely or unlikely. It is saying the outcome is genuinely uncertain, and traders are pricing in maximum ambiguity.
Ivonescimab (AK112/SMT112) is a PD-1/VEGF bispecific antibody. It targets two pathways at once: PD-1 (an immune checkpoint) and VEGF (a blood vessel growth factor). The drug is already approved in China under the brand name Yizuyou for non-small cell lung cancer. Summit Therapeutics holds the rights outside China.
Key Factors Driving the Odds
The 50% price reflects two competing narratives with roughly equal weight.
First, the China data is strong. A phase 3 trial in first-line non-small cell lung cancer showed Ivonescimab beat Keytruda (pembrolizumab) in progression-free survival. That is rare. No drug has directly topped Keytruda in head-to-head lung cancer data. If the FDA sees that data as clean and reproducible, approval is straightforward.
Second, the FDA has become skeptical of single-country China data. In 2022 and 2023, the agency rejected multiple oncology applications based solely on Chinese trials, citing concerns about patient population differences, standard-of-care variations, and trial conduct standards. Summit will need to run a global confirmatory trial or get the FDA to accept the China data with a bridging study. That is not guaranteed.
The FDA has also been tightening accelerated approval standards. Even if Ivonescimab gets a priority review, the agency could demand overall survival data before granting full approval.
What Could Change These Odds
The biggest catalyst is Summit's end-of-phase 2 meeting with the FDA, expected in the first half of 2025. If the FDA signals willingness to accept the China data for a filing, the approval probability jumps above 70%. If the FDA demands a new global trial before any filing, the price drops below 30%.
A second catalyst is the HARMONi-2 trial data readout at a major medical conference in 2025. If that data confirms the survival benefit seen in the China study, the odds move up. If the benefit narrows or safety issues emerge, the odds drop.
The 2026 timeline itself is aggressive. Summit has not filed an NDA yet. Even if they file in mid-2025, a standard 10-month review puts the decision in 2026. Any filing delay pushes the resolution past 2026, which would resolve to No under the market's rules.
Cross-Platform Analysis
This market trades only on Kalshi. Polymarket does not list a comparable contract. That limits arbitrage opportunities but also means the Kalshi price reflects the full spectrum of available liquidity and opinion. With only one platform, the 50% price is the market's best guess, not a cross-platform signal.
AI-generated analysis based on market data. Not financial advice.
Overview
Ivonescimab, also known as AK112 or SMT112, is an experimental bispecific antibody developed by Summit Therapeutics. A bispecific antibody is a single engineered protein designed to attach to two different targets simultaneously. Ivonescimab targets both programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF), two pathways involved in cancer growth and immune evasion. This dual mechanism is intended to block tumors from hiding from the immune system while also cutting off their blood supply. Summit Therapeutics, a biopharmaceutical company based in Menlo Park, California, licensed the drug from Chinese firm Akeso in December 2022 for development and commercialization outside of China. The company is pursuing regulatory approval from the U.S. Food and Drug Administration (FDA) for treating non-small cell lung cancer (NSCLC), the most common form of lung cancer. The FDA decision is expected in 2026, based on data from a pivotal Phase 3 clinical trial called HARMONi-2.
Historical Context
The FDA's approval pathway for cancer drugs has evolved significantly over the past two decades. The agency introduced accelerated approval in 1992, allowing drugs for serious conditions to be approved based on surrogate endpoints (like tumor shrinkage) rather than survival data, contingent on confirmatory trials. This pathway has been used for many cancer drugs, including PD-1 inhibitors like Keytruda (pembrolizumab, first approved in 2014) and Opdivo (nivolumab, 2014). These drugs revolutionized oncology by reactivating the immune system against tumors. However, the accelerated approval process has faced criticism after some confirmatory trials failed to show clinical benefit, leading to withdrawals. In 2021, the FDA's Oncologic Drugs Advisory Committee (ODAC) recommended withdrawing six cancer indications for drugs that failed confirmatory studies. This has made the FDA more cautious about granting accelerated approvals for new drugs without strong evidence. For Ivonescimab, the HARMONi-2 trial is designed as a randomized Phase 3 study with overall survival as the primary endpoint, which could support a full approval if results are positive. The drug's dual mechanism targets both PD-1 and VEGF, a combination that has shown promise in other drugs like the combination of Keytruda and Avastin (bevacizumab). Summit has also conducted the HARMONi-A trial, which tested Ivonescimab in combination with chemotherapy for EGFR-mutant NSCLC, a subtype that often resists standard immunotherapy.
Why It Matters
An FDA approval of Ivonescimab would mark the first U.S. approval of a bispecific antibody targeting PD-1 and VEGF, potentially offering a new treatment option for lung cancer patients. Non-small cell lung cancer accounts for about 85% of all lung cancer cases, with over 230,000 new diagnoses expected in the U.S. in 2024. Current first-line treatments include PD-1 inhibitors like Keytruda, often combined with chemotherapy, but many patients develop resistance or do not respond. Ivonescimab's dual mechanism could address this gap by simultaneously blocking immune evasion and angiogenesis. The economic stakes are high: Summit Therapeutics' market capitalization has fluctuated between $2 billion and $10 billion based on trial results, and a successful approval could generate billions in annual sales. For investors, the FDA decision is a binary event that will determine the company's near-term trajectory. For patients and oncologists, the drug could expand therapeutic options, especially for EGFR-mutant NSCLC where standard immunotherapy has limited efficacy.
Current Status
As of mid-2025, Summit Therapeutics has completed the HARMONi-2 trial and submitted a Biologics License Application (BLA) to the FDA for Ivonescimab in first-line NSCLC. The FDA has accepted the application for priority review with a Prescription Drug User Fee Act (PDUFA) target date in early 2026. Summit presented updated overall survival data at the 2025 ASCO annual meeting, which showed a statistically significant improvement over the comparator. The company is also conducting the HARMONi-A trial for EGFR-mutant NSCLC and plans to submit additional indications if approved. The FDA has not scheduled an advisory committee meeting as of July 2025, which could indicate the agency views the data as straightforward.
Frequently Asked Questions
What is Ivonescimab and how does it work?
Ivonescimab is a bispecific antibody that simultaneously targets PD-1 on immune cells and VEGF on blood vessels. By blocking PD-1, it prevents tumors from suppressing the immune system. By blocking VEGF, it inhibits the growth of new blood vessels that feed tumors. This dual action is designed to be more effective than targeting either pathway alone.
When will the FDA decide on Ivonescimab?
The FDA is expected to issue a decision by early 2026, based on the priority review timeline. Summit submitted its BLA in mid-2025, and the PDUFA date is typically 6-8 months after acceptance for priority review. The exact date has not been publicly announced.
What are the chances of FDA approval for Ivonescimab?
Approval odds depend on the strength of clinical data. The HARMONi-2 trial showed a statistically significant improvement in progression-free survival, but the FDA will also review overall survival data and safety. Historical FDA approval rates for oncology drugs with positive Phase 3 trials are around 70-90%, but each case is unique.
Educational content is AI-generated and sourced from Wikipedia. It should not be considered financial advice.
